Kymera Therapeutics Inc. (KYMR)
NASDAQ (NMS) NASDAQ (NMS) Primary 
XKLS 
Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates
Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.97 per share versus the Zacks Consensus Estimate of a loss of $0.77. This compares to a loss of $0.88 per share a year ago.
KYMR Initiates Dosing in Mid-Stage Asthma Study of Lead Candidate
Kymera Therapeutics begins phase IIb dosing of oral KT-621 in eosinophilic asthma patients, targeting STAT6, with top-line BREADTH study data expected in late 2027.
Kymera Therapeutics (KYMR) Upgraded to Buy: Here's Why
Kymera Therapeutics (KYMR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
KYMR Skyrockets 82.4% in a Year: More Upside Potential in 2026?
KYMR rallied 82% in a year as KT-621 delivered strong phase Ib BroADen data and earned FDA Fast Track for atopic dermatitis.
KYMR Stock Surges on Upbeat Data From KT-621 Atopic Dermatitis Study
Kymera jumps after phase Ib study data show KT-621 delivers strong STAT6 degradation and broad clinical activity in patients with atopic dermatitis.
This Drugmaker's Stock Is Soaring Over 40% Monday
Kymera Therapeutics (KYMR) shares surged over 40% to an all-time high Monday afternooon after the drugmaker reported positive results from an early test of an oral anti-inflammatory drug.
Kymera's KT-621 Shines: Phase 1b Data Boosts Momentum
Kymera Therapeutics, Inc. reported robust Phase 1b results for KT-621, showing deep STAT6 degradation and strong clinical efficacy in atopic dermatitis. KT-621 demonstrated a favorable safety profile, rapid onset, and meaningful biomarker and symptom improvements, supporting advancement to Phase 2b trials in AD and asthma. KYMR's $4.8B market cap reflects its validated protein-degradation platform and KT-621's commercial potential in large, crowded Type-2 inflammatory disease markets.
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?
Kymera Therapeutics (KYMR) reported earnings 30 days ago. What's next for the stock?
Kymera Therapeutics, Inc. (KYMR) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Kymera Therapeutics, Inc. (KYMR) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Kymera Trades Near 52-Week High: Time to Buy, Sell or Hold the Stock?
KYMR hits a 52-week high as optimism builds around KT-621's progress and upcoming data in atopic dermatitis.
Kymera Therapeutics, Inc. (KYMR) Presents at UBS Global Healthcare Conference 2025 Transcript
Kymera Therapeutics, Inc. ( KYMR ) UBS Global Healthcare Conference 2025 November 10, 2025 11:45 AM EST Company Participants Jared Gollob - Chief Medical Officer Conference Call Participants Xiaochuan Dai - UBS Investment Bank, Research Division Presentation Xiaochuan Dai UBS Investment Bank, Research Division All right. Well, thank you, everyone, for joining us in our fireside chat with Kymera Therapeutics.
Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Misses Revenue Estimates
Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.9 per share versus the Zacks Consensus Estimate of a loss of $0.71. This compares to a loss of $0.82 per share a year ago.
